Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Annalen Bleckmann

Showing results (51-60 of 110) with videos related to

Pageof 11
Sort By:
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|May 3, 2017
Long-term outcomes after TAVI in patients with different types of aortic stenosis: the conundrum of low flow, low gradient and low ejection fractionMiriam Puls, Kerstin Pia Korte, Annalen Bleckmann, et al.
Oncotarget|September 22, 2021
Polyclonal on- and off-target resistance mutations in an <i>EML4-ALK</i> positive non-small cell lung cancer patient under ALK inhibitionMarcel Kemper, Georg Evers, Arik Bernard Schulze, et al.
International Journal of Molecular Sciences|December 24, 2021
Metabolomic Profiling of Blood-Derived Microvesicles in Breast Cancer PatientsJudith Buentzel, Henry Gerd Klemp, Ralph Kraetzner, et al.
Anticancer Research|September 15, 2019
Sarcopenia as Prognostic Factor in Lung Cancer Patients: A Systematic Review and Meta-analysisJudith Buentzel, Judith Heinz, Annalen Bleckmann, et al.
Journal of Extracellular Vesicles|March 7, 2024
PD-L1 on large extracellular vesicles is a predictive biomarker for therapy response in tissue PD-L1-low and -negative patients with non-small cell lung cancerNadja Schöne, Marcel Kemper, Kerstin Menck, et al.
Journal of Molecular Cell Biology|December 16, 2014
Tumor-derived microvesicles mediate human breast cancer invasion through differentially glycosylated EMMPRINKerstin Menck, Christian Scharf, Annalen Bleckmann, et al.
Therapeutic Advances in Medical Oncology|March 31, 2022
Real-world multicentre analysis of neoadjuvant immunotherapy and chemotherapy in localized or oligometastatic non-small cell lung cancer (KOMPASSneoOP)Martin Faehling, Hanno Witte, Martin Sebastian, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|August 20, 2014
Impact of frailty on short- and long-term morbidity and mortality after transcatheter aortic valve implantation: risk assessment by Katz Index of activities of daily livingMiriam Puls, Bettina Sobisiak, Annalen Bleckmann, et al.
Cancers|March 25, 2022
High Expression of NT5DC2 Is a Negative Prognostic Marker in Pulmonary AdenocarcinomaArik Bernard Schulze, Anna Kuntze, Lars Henning Schmidt, et al.
Translational Lung Cancer Research|May 17, 2023
High expression of transcription factor POU2F1 confers improved survival on smokers with lung adenocarcinoma: a retrospective study of two cohortsArik Bernard Schulze, Daniela Vanessa Wenge, Georg Evers, et al.
Pageof 11

Showing results (51-60 of 110) with videos related to

Sort By:
Pageof 11
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|May 3, 2017
Long-term outcomes after TAVI in patients with different types of aortic stenosis: the conundrum of low flow, low gradient and low ejection fractionMiriam Puls, Kerstin Pia Korte, Annalen Bleckmann, et al.
Oncotarget|September 22, 2021
Polyclonal on- and off-target resistance mutations in an <i>EML4-ALK</i> positive non-small cell lung cancer patient under ALK inhibitionMarcel Kemper, Georg Evers, Arik Bernard Schulze, et al.
International Journal of Molecular Sciences|December 24, 2021
Metabolomic Profiling of Blood-Derived Microvesicles in Breast Cancer PatientsJudith Buentzel, Henry Gerd Klemp, Ralph Kraetzner, et al.
Anticancer Research|September 15, 2019
Sarcopenia as Prognostic Factor in Lung Cancer Patients: A Systematic Review and Meta-analysisJudith Buentzel, Judith Heinz, Annalen Bleckmann, et al.
Journal of Extracellular Vesicles|March 7, 2024
PD-L1 on large extracellular vesicles is a predictive biomarker for therapy response in tissue PD-L1-low and -negative patients with non-small cell lung cancerNadja Schöne, Marcel Kemper, Kerstin Menck, et al.
Journal of Molecular Cell Biology|December 16, 2014
Tumor-derived microvesicles mediate human breast cancer invasion through differentially glycosylated EMMPRINKerstin Menck, Christian Scharf, Annalen Bleckmann, et al.
Therapeutic Advances in Medical Oncology|March 31, 2022
Real-world multicentre analysis of neoadjuvant immunotherapy and chemotherapy in localized or oligometastatic non-small cell lung cancer (KOMPASSneoOP)Martin Faehling, Hanno Witte, Martin Sebastian, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|August 20, 2014
Impact of frailty on short- and long-term morbidity and mortality after transcatheter aortic valve implantation: risk assessment by Katz Index of activities of daily livingMiriam Puls, Bettina Sobisiak, Annalen Bleckmann, et al.
Cancers|March 25, 2022
High Expression of NT5DC2 Is a Negative Prognostic Marker in Pulmonary AdenocarcinomaArik Bernard Schulze, Anna Kuntze, Lars Henning Schmidt, et al.
Translational Lung Cancer Research|May 17, 2023
High expression of transcription factor POU2F1 confers improved survival on smokers with lung adenocarcinoma: a retrospective study of two cohortsArik Bernard Schulze, Daniela Vanessa Wenge, Georg Evers, et al.
Pageof 11